Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically confirmed CD20 +ve follicular lymphoma grades I to IIIa.~* Patients with at least one of the following symptoms requiring initiation of treatment: (as outlined by the modified BNLI/GELF criteria below)~  * Nodal mass \> 7cm in its greater diameter~ * B symptoms~ * Elevated serum LDH or beta2-microglobulin~ * involvement of at least 3 nodal sites (each with a diameter \> 3 cm)~ * symptomatic splenic enlargement~ * compressive syndrome~* Patients must have an ECOG performance status less than or equal to 2 and an anticipated survival of at least 6 months.~* Patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet count of above 100,000/mm3 post 4 weeks of unlabelled Rituximab. A hemoglobin \>= 8.0 g/dl~* Patients must have adequate renal function (defined as calculated creatinine clearance \> 30 ml/mn), hepatic function (defined as total bilirubin \<1.5 times upper limit of normal), and hepatic transaminases (defined as AST \<5 times upper limit of normal)~* Patients must have given informed consent prior to study entry.~Exclusion Criteria:~* Patients with a mean of \>20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction Rituximab therapy.~* Transformed follicular lymphoma and discordant lymphoma~* Patients with active obstructive hydronephrosis.~* Patients with initial disease bulk greater than 10cm.~* Patients with evidence of active infection requiring i.v. antibiotics at the time of study entry.~* Patients with congestive heart failure stage III or IV of NYHA classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation.~* Patients with left VEF \< 40%~* Patients with large pleural or peritoneal effusions.~* Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.~* Known Hypersensitivity to murine antibodies or proteins~* Patients who are pregnant or breast-feeding. Male and female patients must agree to use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody therapy.~* Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fractionated Initial Zevalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).